Tuberculosis Testing Market

Market Overview

The "Global Tuberculosis Testing Market" is expected to grow at a high CAGR of 5.2% during the forecasting period (2021-2028).

Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide, and the leading cause of death from a single infectious agent. It is caused by the bacillus Mycobacterium tuberculosis, which is spread when sick people with TB expel bacteria into the air, for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. Tuberculosis testing can be defined as the most commonly used diagnostic tool for tuberculosis. With a timely diagnosis and treatment with first-line antibiotics for 6 months, most people who develop TB can be cured, and onward transmission of infection curtailed. The number of TB cases occurring each year can also be driven down by reducing the prevalence of health-related risk factors for TB providing preventive treatment to people.

Download free sample: https://www.datamintelligence.com/download-sample/tuberculosis-testing-market

Market Dynamics

The market is driven by the increasing number of coronavirus cases, increasing the number of tuberculosis patients. According to the World Health Organization (WHO), in 2017, an estimated 4.4 million people fell ill with TB, and an estimated 638,000 died because of the disease, which is more than half of global TB deaths. Factors propelling the market's growth include the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing R&D investments, intensive product pipelines, and increasing government initiatives in the emerging markets. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to the WHO Global TB program, it has implemented a systematic and dynamic process used to evaluate technologies and develop policies, which has enhanced the market's growth.

The prevalence rate of tuberculosis is also increasing every year, along with the number of government awareness programs that influence people to opt for diagnostic tests (like radiographic tests), which are expected to drive the market during the forecast period. The market is also expected to witness growth as there is an opportunity for players in the market to accelerate their pipeline diagnostic products' market approval by spurring the fundamental research in TB. Additionally, technological developments in genomics and proteomics can be leveraged by diagnostic providers to hasten product development in TB diagnostics.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the results of these initiatives. This has led to a subsequent upsurge in demand for diagnostic tests and the TB diagnostics market.

Furthermore, the government and independent healthcare organizations have undertaken initiatives to control this infectious disease's proliferation. Creating awareness about the importance of diagnosis is vital in increasing the screening and diagnosis rates, further helping the TB diagnostics market flourish. This factor is driving the growth of the market in the forecast period. For instance, the Revised National Tuberculosis Control Program (RNTCP) in India focuses on performing TB screening and providing greater access to treatment through free diagnosis & treatment programs. Besides, private-public partnerships under this program are boosting the diagnosis rate.

Population above the age of 60 is the target population for the TB diagnostics market as this demographic is susceptible to infectious diseases. The growing geriatric population base, as a result, is driving the growth of the market.

However, drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimens and incorrect dosage forms lead to drug resistance in TB patients undergoing treatment, restraining the market's growth.

Segment Analysis

– By Test Type

·      Nuсlеіс Асіd Теѕtіng*

·      Cytokine Detection Assay

·      Detection of Latent Infection

·      Сulturе Ваѕеd Теѕtѕ

·      Drug Ѕuѕсерtіbіlіtу Теѕtіng

·      Others

– By End-User

·      Hospital laboratories*

·      Research laboratories

·      Clinics laboratories

·      Diagnostic center

Geographical Presentation

The global tuberculosis testing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, Asia-Pacific dominated the global tuberculosis testing market and is expected to grow at the highest CAGR during the forecast period. The growth of the market in the region is attributed to tuberculosis's high burden and the rapid proliferation of this disease. The increasing prevalence of TB in Japan helps in the TB diagnostics market's growth. The high prevalence of TB creates an urgent demand for effective and quick diagnosis of the disease. Besides, in countries such as India, according to the recent budget announcement, the Government of India aims to eliminate tuberculosis by 2025, which is expected to act as one of the major factors for the growth of the Asia-Pacific market forecast period.

Infectious and Endemic Disease Control in China, RNTCP in India, and the National TB program in Afghanistan are the few programs planned by local healthcare agencies to contain the incidence and ensure equitable access to diagnosis. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for controlling this communicable disease.

The Middle East and Africa region are expected to have the third-largest share due to the relatively faster pace because of the increasing instances of tuberculosis. The increasing government focuses on establishing regulations to approve tuberculosis tests and growing focus on awareness programs by the tuberculosis diagnosis testing kits manufacturing companies. North America, powered by the U.S., is one of the major markets for the global tuberculosis testing market.

In October 2018, BD, a leading global medical technology company, announced the BD MAX™ MDR-TB panel availability in Europe. BD launched the first automated liquid culture system, the BD BACTEC™ MGIT™ system, for comprehensive drug susceptibility and resistance testing.

Competitive Analysis

The global tuberculosis testing market is highly competitive, with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH, are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the Treatment of COVID-19 across the globe.

For instance, in July 2016, bioMérieux launched a novel CE-marked database and reagents kit VITEK MS to identify TB. This new product launch is anticipated to help the company increase its market share.

In September 2017, Thermo Fisher Scientific, Inc. acquired Alfa Aesar for USD 400 million. Alfa Aesar is involved in providing laboratory and research chemicals ranging from catalysts, reagents, analytical, and labeling products. Their combined strength in laboratory chemical development and production is expected to support their growth in this sector.

View Full Report: https://www.datamintelligence.com/research-report/tuberculosis-testing-market

Enquiry Before Buying: https://www.datamintelligence.com/enquiry/tuberculosis-testing-market

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com